$25 Million Gift to Medical Center Enhances New Initiative for Treatment of ALS

Feb. 7, 2013Bookmark and Share

Daniel L. Doctoroff, Bloomberg LP CEO and president; David M. Rubenstein, co-CEO of The Carlyle Group; and Bloomberg Philanthropies today unveiled Target ALS, a $25 million three-year initiative to streamline discovery of new approaches to treating ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease).

L-R: Don W. Cleveland, University of California, San Diego; Kevin C. Eggan, Harvard; Christopher E. Henderson, co-director of the Motor Neuron Center at Columbia University Medical Center; Daniel L. Doctoroff, Bloomberg LP CEO and president; and Jeffrey Rothstein, director of the Robert Packard Center for ALS Research at Johns Hopkins University, met at Henderson’s lab at Columbia University Medical Center to mark the launch of Target ALS. (Image credit: Columbia University Medical Center)
L-R: Don W. Cleveland, Kevin C. Eggan, Christopher E. Henderson, Daniel L. Doctoroff and Jeffrey Rothstein met at Henderson’s lab at Columbia University Medical Center to mark the launch of Target ALS.
Image credit: Columbia University Medical Center

“Finding a cure for ALS requires that we think differently about how to tackle this debilitating disease,” said Doctoroff. “While ALS scientists have made great progress in the last few years, their research too often occurs in silos, impeding discovery. Target ALS will provide an organizational framework for the world’s leading ALS researchers to share and coordinate their findings so that we can make progress toward therapies and a cure.”

Target ALS is the next phase of an accelerated research initiative of Project A.L.S., a New York-based foundation focused on finding and funding a cure for ALS, and the Packard Center for ALS Research at Johns Hopkins University, which was announced in January 2010. Target ALS will build on the rapid scientific progress of the past three years through a new collaboration that pools the efforts of dozens of scientists and laboratories into an efficient organization focused on new targets for ALS therapeutics. The immediate goal is to seed an array of drug-development programs at pharmaceutical and biotech companies, based on cutting-edge data generated by Target ALS scientists. Target ALS will identify and transfer candidate therapeutic targets—molecular events that occur in ALS patients that, when blocked, can slow or arrest disease progression. The long-term goal is to find effective therapies for ALS.

Researchers and laboratories from around the world participating in Target ALS will benefit from a central organization through which to share ideas, progressand discoveries, as well as a source of funding to develop new collaborative projects. A feature of the new consortium is the Target ALS Core Facilities, which will provide ALS investigators with access to key technologies that are too complex or costly to set up in each individual laboratory.

“With fresh resources and determined collaboration, we can make steady progress toward a cure for this devastating disease,” said Rubenstein. “Dan, Mike and I hope these resources will serve as a unifying catalyst for the great work that is being done around the world to cure and prevent ALS.”

“Collaboration is essential to build on the real progress that’s being made in the field of ALS research,” said Michael R. Bloomberg, philanthropist and Mayor of New York City. “I’m proud to join Dan and David to launch this innovative new project and bring together the scientific, academic, healthcare and business communities to stop this horrible disease once and for all.”

Scientific director Christopher E. Henderson and executive director Manish Raisinghani will jointly manage the program. Henderson is the Gurewitsch/Vidda Professor of Rehabilitation and Regenerative Medicine and co-director of the Motor Neuron Center and the Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research at Columbia University Medical Center. The project will also benefit from the vision of special consultant Zach Hall, who is a former director of the National Institute of Neurological Disorders and Stroke and was the first president of the California Institute for Regenerative Medicine.

“Target ALS will generate a pipeline of candidate therapeutic targets that will provide a common language for Target ALS and pharma and biotech companies, with whom we have initiated a dialogue to define their needs and expectations,” said Henderson.

“By coordinating and supporting the work of leading ALS scientists and engaging pharma and biotech, Target ALS provides a new way of organizing science that will hasten the development of much-needed therapies for this debilitating disease,” said Hall.

“We are extremely grateful to Dan, David and Bloomberg Philanthropies for their generosity and for recognizing the great promise of the research led by Dr. Henderson and his colleagues both here at Columbia and at our collaborating institutions,” said Lee Goldman, dean of the Faculties of Health Sciences and Medicine, Columbia University Medical Center, and executive vice president for Health and Biomedical Sciences, Columbia University.

Reflecting the wide range of institutions involved, Target ALS’s strategy will receive oversight from a research advisory board, and funding will be conditional on positive evaluation by an independent review committee.

“With the recent discovery of new genes and disease mechanisms, ALS research is now in its most exciting phase ever. Target ALS will allow us to make a determined push toward rational therapeutic strategies for this terrible disease,” said Jeffrey Rothstein, director of the Robert Packard Center for ALS Research at Johns Hopkins University and chair of the Target ALS Research Advisory Board.

The objectives of Target ALS build upon, and are complementary to, those of existing ALS-related foundations and centers, with whom collaborations and coordination are an important part of the Target ALS strategy.

“Project A.L.S. is proud to have launched Target ALS, a systemized approach to screening ALS therapies. Project A.L.S. will continue to launch new ideas that we hope will feed the Target ALS mission,” said Valerie Estess, director of research for Project A.L.S.

“We are eager to partner with Target ALS to provide access to core facilities for some of the scientists we support worldwide,” said Lucie Bruijn, chief scientist of the ALS Association, which funds research, engages in advocacy, and provides care and support to ALS patients and families.

“Testing candidate targets in predictive disease models is a high priority and we are pleased to collaborate with Target ALS in this area,” said Melanie Leitner, chief scientific officer of Prize4Life, Inc., a foundation dedicated to accelerating the discovery of treatments and cures for ALS.

—by Columbia University Medical Center Staff

Top
Columbia on Facebook Columbia on Twitter Columbia on Google+ Columbia on iTunes U Columbia News RSS Columbia on YouTube

Multimedia

FDA-Approved Drug Restores Hair in Patients with Alopecia Areata.
Columbia's Leadership in Climate Research

Columbia in the Headlines

The New York Times, Oct 27
To Improve a Memory, Consider Chocolate

Scientific American, Oct 24
Caleb Scharf: Complex Life Owes Its Existence To Parasites?

Scientific American, Oct 21
Caleb Scharf: Interview: The New moon

The New York Times, Oct 20
Robotic Surgery Report Card

The New Yorker, Oct 27
Dept. of Solutions: All Hands on Deck